市場調查報告書
商品編碼
1373361
胰島素輸送設備市場規模 - 按產品(胰島素幫浦、胰島素筆、胰島素筆針頭、胰島素噴射注射器、胰島素注射器)、最終用途和全球預測,2023 - 2032 年Insulin Delivery Devices Market Size - By Product (Insulin Pumps, Insulin Pens, Insulin Pen Needles, Insulin Jet Injectors, Insulin Syringes), By End-use & Global Forecast, 2023 - 2032 |
由於人們對家庭醫療保健解決方案的偏好日益增加,加上易於使用的設備不斷進步,胰島素輸送設備市場規模預計從 2023 年到 2032 年將以 10.6% 的年複合成長率擴大。
人們越來越重視以患者為中心的護理以及在家中管理慢性疾病的便利性,這使得方便用戶使用型攜帶式胰島素輸送設備的採用激增,使患者能夠自行注射胰島素。此外,產業參與者正在對策略性措施進行大量投資,以促進遠端監控和遠距醫療服務的新進步。例如,2023 年5 月,美敦力公司收購了EOFlow Co. Ltd.,該公司是EOPatch (R) 設備的生產商,該設備是一種無管、穿戴式、完全拋棄式的胰島素輸送系統,以擴大其能力,以滿足糖尿病患者更複雜的需求。
胰島素輸送設備產業分為產品、最終用途和地區。
胰島素筆產品領域的市場佔有率預計將在 2023 年至 2032 年期間獲得顯著成長,因為其方便用戶使用且方便的功能可為患者提供高效且謹慎的胰島素注射方法。具有整合劑量追蹤和連接功能的智慧胰島素筆開發的技術進步激增,將進一步增加產品需求。例如,2022 年12 月,Biocorp 獲得了FDA 510(k) 批准,將其Mallya 智慧醫療設備商業化,該設備用於連接胰島素筆,自動收集和記錄重要的治療資訊,以便傳輸到專用數位應用程式。
預計在 2023 年至 2032 年間,胰島素輸送設備產業將從醫院和診所終端使用領域開始成長。醫院和診所是糖尿病管理的主要中心,進一步需要使用先進的胰島素輸送設備來滿足不同的病患需求。全球糖尿病發生率不斷上升,導致醫療機構對高效、可靠的胰島素輸送解決方案的需求增加,也推動了該領域的成長。
從地區來看,歐洲胰島素輸送設備產業在2022 年呈現顯著成長,預計在2023 年至2032 年期間將實現強勁的年複合成長率,這主要得益於糖尿病盛行率不斷上升、強大的醫療基礎設施以及積極主動的糖尿病管理方法。此外,政府的支持性政策和對改善患者治療結果的日益關注正在提高該地區糖尿病護理的質量,從而展現出該行業利潤豐厚的成長前景。例如,2023年6月,Insulet公司宣佈在英國推出Omnipod 5自動胰島素輸送系統,以減輕兩歲及以上第1型糖尿病患者的負擔並提高生活品質。
Insulin Delivery Devices Market size is anticipated to expand at 10.6% CAGR from 2023 to 2032, driven by the increasing preference for home-based healthcare solutions coupled with the rising advancements in easy-to-use devices.
The rising emphasis on patient-centric care and the convenience of managing chronic diseases at home is surging the adoption of user-friendly and portable insulin delivery devices for enabling patients to self-administer insulin. Moreover, industry participants are making massive investments in strategic initiatives for new advancements for facilitating remote monitoring and telemedicine services. For instance, in May 2023, Medtronic plc acquired EOFlow Co. Ltd., the producer of the EOPatch® device, a tubeless, wearable, and entirely disposable insulin delivery system, for broadening its capacity to meet the more complex needs of diabetics.
The insulin delivery devices industry is segmented into product, end-use, and region.
The market share from the insulin pens product segment is anticipated to gain significant traction from 2023-2032 due to its user-friendly and convenient features for offering patients an efficient and discreet method for insulin administration. The surge in technological advancements for the development of smart insulin pens with integrated dose tracking and connectivity features will further augment the product demand. For instance, in December 2022, Biocorp acquired the FDA 510(k) approval to commercialize its Mallya smart medical device for connecting to insulin pens to automatically gather and record important treatment information for transmission to dedicated digital application.
Insulin delivery devices industry is projected to grow from the hospitals & clinics end-use segment between 2023 and 2032. Hospitals and clinics serve as primary hubs for diabetes management, further necessitating the usage of advanced insulin delivery devices to cater to diverse patient needs. The rising prevalence of diabetes cases worldwide leading to the heightened demand for efficient and reliable insulin delivery solutions in healthcare facilities is also propelling the segment growth.
Regionally, the Europe insulin delivery devices industry exhibited significant growth in 2022 and is estimated to record robust CAGR from 2023-2032, driven by the increasing prevalence of diabetes, strong healthcare infrastructure, and the proactive approach to diabetes management. Additionally, supportive government policies and the increasing focus on improving patient outcomes are enhancing the quality of diabetes care in the region, thereby demonstrating lucrative growth prospects for the industry. For instance, in June 2023, Insulet Corporation announced the launch of its Omnipod 5 Automated Insulin Delivery System in the U.K. to ease the burden and improve the quality of life for type 1 diabetic patients aged two years and above.